Liso-Cel Approved for Second-Line Large B-Cell Lymphoma
The approval builds off of liso-cel's (Breyanzi) previous indication for third-line or later treatment in LBCL.
The FDA has approved Bristol Myers Squibb’s supplemental biologics license application for lisocabtagene maraleucel (liso-cel; Breyanzi) as second-line therapy for patients with large B-cell lymphoma (LBCL).1
The chimeric antigen receptor (CAR) T-cell therapy was originally approved in February 2021 for adults with relapsed or refractory diffuse LBCL who have not responded to at least 2 other treatments based off data from the pivotal phase 3 TRANSFORM (NCT03575351) trial.2
In the second-line setting, liso-cel recently showed good efficacy and patient-reported outcome (PRO) data in the phase 2 TRANSCEND study (NCT03483103), updated data from which were presented at the 2022 American Society of Clinical Oncology (ASCO) meeting, held June 3-7, 2022, in Chicago, Illinois.3,4
The TRANSCEND study dosed 61 participants that had disease that relapsed after or was refractory to first-line chemotherapy. These participants were followed-up for a median of 12.3 months (range, 1.2–26.5). Investigators found that overall response rate (ORR) was 80% and complete response rate (CR) was 54%. Median duration of response (DOR) was 12.1 months, progression-free survival (PFS) was 9.0 months, and median overall survival (OS) has not been reached.
WATCH NOW: Frederick Locke, MD, on the Impact Potential of CAR T-Cell Therapies in Hematologic Malignancies
Investigators assessed PROs and found that completion rates were high (≥ 80%) across most visits for all measures. Baseline European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients (EORTC QLQ-C30) mean fatigue scores were worse by at least 10 points at baseline compared to a general noncancer population. These scores, along with pain domain scores, Functional Assessment of Cancer Therapy – lymphoma subscale, and EuroQol Visual Analogue Scale scores improved significantly by least square means through day 545.
Patients also reported that lymphoma symptoms improved in a clinically meaningful way. No outcomes significantly worsened and 70% of patients demonstrated meaningful improvement in FACT-LymS at month 6.
Liso-cel has been well-tolerated, with treatment-emergent adverse events (TEAE) in TRANSCEND that included neutropenia (51%), fatigue (39%), and CRS (38%), including 1 case of grade 3 CRS (2%). Neurological events occurred in 31% of participants, 5% (n = 3) of which were grade 3 cases. AEs resolved with the use of tocilizumab (7%), corticosteroids (3%), or both (20%). Overall, grade 3 TEAEs occurred in 79% of participants, with grade 5 cases in 2 patients due to COVID-19. Two patients (3%) had grade 3/4 infections and 15 (25%) had at least grade 3 neutropenia at Day 29.
Liso-cel's supplemental biologics license application received priority review in February 2021.5 The therapy was also approved by the EMA in April 2022 for the treatment of relapsed/refractory DLBCL, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) in patients who have received 2 or more lines of systemic treatment.6
REFERENCES
1.U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy. News release. Bristol Myers Squibb. June 24, 2022. https://news.bms.com/news/details/2022/U.S.-FDA-Approves-Bristol-Myers-Squibbs-CAR-T-Cell-Therapy-Breyanzifor-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspx
2. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. News release. FDA. February 5, 2021. https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-adults-with-relapsed-or-refractory-large-b-cell-lymphoma-301223275.html
3. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagenemaraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study. Presented at: 2022 ASCO Annual Meeting, June 3-7, 2022, Chicago, Illinois. Abstract #7062
4. Gordon LI, Hoda D, Shi L, et al. Lisocabtagenemaraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study. Presented at: 2022 ASCO Annual Meeting, June 3-7, 2022, Chicago, Illinois. Abstract #6567
5. US Food and Drug Administration (FDA) accepts for priority review Bristol Myers Squibb’s supplemental biologics license application for Breyanzi (lisocabtagenemaraleucel) as a second-line therapy for relapsed or refractory large B-cell lymphoma. News release. Bristol Myers Squibb; February 17, 2022. Accessed February 17, 2022. https://bit.ly/3Bujynp
6. Bristol Myers Squibb receives European Commission approval for CAR T cell therapy Breyanzi (lisocabtagenemaraleucel) for certain forms of relapsed or refractory large B-cell lymphoma. News release. Bristol Myers Squibb. April 5, 2022. Accessed April 8, 2022. https://bit.ly/3LPwb0l
News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025
March 9th 2025In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest news and expert insights in gene therapy for hemophilia, which is among the most common of these disorders.
